#United States #St. Louis #Histotripsy #Mercy Hospital #Edison System

Transforming Liver Tumor Treatment with Histotripsy

In a groundbreaking development in the field of cancer treatment, Mercy Hospital St. Louis is preparing to introduce the Edison® Histotripsy System, a revolutionary technology that promises to treat liver tumors without the need for traditional surgical methods. This innovative approach may sound like something out of a sci-fi movie, but it is very real and set to begin serving patients in late April.

A New Era in Cancer Care

Histotripsy is an advanced, non-invasive treatment that utilizes focused ultrasound waves to precisely target and destroy tumor tissue. Instead of resorting to surgery, chemotherapy, or radiation—methods that can be daunting and draining for patients—this technology liquefies tumors using ultrasonic pulses that create microscopic bubbles within the tumor tissue. This process avoids damaging surrounding healthy tissues, making it a significantly gentler approach to cancer treatment.

Dr. Peter DiPasco, a surgical oncologist at Mercy and chief physician executive for Mercy's cancer services, emphasizes how transformative this technology is for patients. "For those diagnosed with liver cancer, this presents a whole new array of treatment possibilities that they may have never experienced before. Not only does it bring hope, but it does so with significantly reduced pain and discomfort."

Understanding Histotripsy

The functioning of the Edison Histotripsy System centers on the principle of energy delivery through sound waves. When administered, these sound waves generate tiny gas bubbles. When these bubbles expand and collapse rapidly due to the focused ultrasound, they effectively disintegrate the tumor tissue within the liver. This distinct method not only ensures a higher safety profile but also entails no incisions or invasive procedures.

Mercy Hospital is proud to be the first institution in Missouri to implement this state-of-the-art technology, placing it among a select group of around 100 hospitals in the United States already equipped with the Edison system.

Extensive Study and Proven Results

Histotripsy technology has been under investigation and development for over 20 years and has been validated through various clinical trials, demonstrating its effectiveness in treating both primary liver tumors and metastatic cancers. Current trials are also exploring its applicability in treating solid renal tumors and pancreatic adenocarcinoma, showcasing its versatility across different types of cancer.

In addition to his enthusiasm for the technology, Dr. Gautum Agarwal, a urologic oncologist at Mercy and director of Mercy Precision Medicine, acknowledges the significance of being able to access such innovative tools to target difficult tumors. "The potential applications of histotripsy are exciting, especially for hard-to-reach tumors where traditional options may fall short," Dr. Agarwal notes.

Commitment to Advanced Healthcare

Introducing histotripsy to Mercy's liver care program reflects the organization’s dedication to providing cutting-edge, minimally invasive treatment options to its patients. Mercy has long prioritized innovative care solutions, serving millions across several states with a network of healthcare services. As one of the largest health systems in the U.S., Mercy is continuously recognized for its commitment to quality patient experiences and effective healthcare practices.

As this technology gets ready to launch, patients at Mercy Hospital in St. Louis will soon have access to a method of treatment that not only enhances their quality of life but also stands as a testament to what modern medicine can achieve in the fight against cancer. For more information about the Edison System and histotripsy, visit histosonics.com.